Hepatology
Adenoviral infection boosts tumor necrosis factor tolerance to halt hepatitis
Published in Gene Therapy Weekly, October 16th, 2003
According to recent research published in the Journal of Immunology, "effects of adenoviral infection on in vivo responses to lipopolysaccharide (LPS) mediated by tumor necrosis factor (TNF)-alpha were evaluated in a murine model. Adenovirus-infected mice showed decreased mortality from fulminant hepatitis induced by administration of LPS or staphylococcal enterotoxin B in the presence of D-galactosamine."
"Importantly, TNF-alpha resistance genes within adenoviral E3 region were not required, because E1,E3-deleted vectors showed similar effects," stated T.O....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2003-10-16)
More Articles from Gene Therapy Weekly
- Head and Neck Cancer
Liposomal conjugation improves adenoviral transduction of squamous cell cancer - Oncology
Nonradioactive iodide stimulates apoptosis in genetically modified cancer cells - Endocrinology
Excess Bcl-2 production reverses programmed cell death in beta cells - Neuroscience
Gene-modified cells correct Parkinson-like disease in animal models - Oncology
Gene expression mechanisms enhance magnetic resonance images of prostate cancer - Orthopedics
Bone morphogenetic protein-4 gene therapy regenerates in vivo bone formation - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
